<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02285218</url>
  </required_header>
  <id_info>
    <org_study_id>4-2014-0073</org_study_id>
    <nct_id>NCT02285218</nct_id>
  </id_info>
  <brief_title>Role of New Adipokines and Hepatokines in Prediction of Patients With Metabolic Syndrome or NAFLD</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the predictive roles of adipokines and hepatokines to detect non-alcoholic
      fatty liver disease (NAFLD), diabetes, or dyslipidmia.

      To examine the association or effects of clinical and biochemical factors (lab results and
      medication, etc.) on serum levels of adipokines and hepatokines in certain subjects with
      non-alcoholic fatty liver disease (NAFLD), diabetes, or dyslipidmia.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>new adipokines</measure>
    <time_frame>To 8h fasting blood sample</time_frame>
    <description>several candidate adipokines and hepatokines to predict diseases will be measured using ELISA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>new hepatokines</measure>
    <time_frame>To 8h fasting blood sample</time_frame>
    <description>several candidate adipokines and hepatokines to predict diseases will be measured using ELISA</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Non-alcoholic Fatty Liver Disease</condition>
  <condition>Type 2 Diabetes</condition>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>1) Normal control</arm_group_label>
    <description>metabolically healthy with no obesity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2) dyslipidemia</arm_group_label>
    <description>high triglyceride levels or LDL-C levels</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3) type 2 diabetes</arm_group_label>
    <description>defined in 'inclusion criteria'</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4) non-alcoholic fatty liver disease</arm_group_label>
    <description>defined in 'inclusion criteria'</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>serum blood sampling</intervention_name>
    <arm_group_label>1) Normal control</arm_group_label>
    <arm_group_label>2) dyslipidemia</arm_group_label>
    <arm_group_label>3) type 2 diabetes</arm_group_label>
    <arm_group_label>4) non-alcoholic fatty liver disease</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma (blood)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects are recruited from either patients who visit out-patient clinics (Diabetes center
        in Severance hospital) or healthy volunteers.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. dyslipidemia 1. serum triglyceride≥150mg/dl, or taking medication to lower
             triglyceride levels (e.g. fibrates, niacin, omega-3, etc.) or 2. serum LDL-C≥100mg/dl,
             or taking medication to lower LDL-C levels (e.g. statin, ezetimibe, etc.)

          2. type 2 diabetes 1. defined according to the ADA guideline (DM definition) or 2. taking
             any anti-diabetic medications

          3. non-alcoholic fatty liver disease (NAFLD) 1. diagnosed as having fatty liver by
             ultrasonogram or 2. diagnosed as having fatty liver by transient elastogram
             (Fibroscan) or 3. diagnosed as having fatty liver by abdomina CT scan

          4. Normal control 1. should not be included in other groups as above and 2. not taking
             any medication related to diabetes and dyslipidemia and 3. BMI &lt;25kg/m2

        Exclusion Criteria:

          1. subjects who refused to agree with informed consents

          2. subjects with organ-transplantation

          3. serum creatinine ≥1.5mg/dl

          4. pregnant women

          5. liver cancer or pancreatic cancer

          6. subjects with chronic hepatitis B or C virus infection

          7. for NAFLD group, subjects with excessive alcohol consumption (men: ≥210g of alcohol
             per week, women: ≥140g of alcohol per week)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bong Soo Cha, MD</last_name>
    <phone>+82-2-2228-1932</phone>
    <email>bscha@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Severance hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bong Soo Cha, MD</last_name>
      <phone>+82-2-2228-1932</phone>
      <email>bscha@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2014</study_first_submitted>
  <study_first_submitted_qc>November 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2014</study_first_posted>
  <last_update_submitted>November 12, 2014</last_update_submitted>
  <last_update_submitted_qc>November 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

